BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37600236)

  • 1. The impact of interaction between verteporfin and yes-associated protein 1/transcriptional coactivator with PDZ-binding motif-TEA domain pathway on the progression of isocitrate dehydrogenase wild-type glioblastoma.
    Osama M; Essibayi MA; Osama M; Ibrahim IA; Nasr Mostafa M; Şakir Ekşi M
    J Cent Nerv Syst Dis; 2023; 15():11795735231195760. PubMed ID: 37600236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma.
    Vigneswaran K; Boyd NH; Oh SY; Lallani S; Boucher A; Neill SG; Olson JJ; Read RD
    Clin Cancer Res; 2021 Mar; 27(5):1553-1569. PubMed ID: 33172899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Efficiency of Verteporfin as a Therapeutic Option in Pre-Clinical Models of Melanoma.
    Lui JW; Xiao S; Ogomori K; Hammarstedt JE; Little EC; Lang D
    J Cancer; 2019; 10(1):1-10. PubMed ID: 30662519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
    Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcatheter arterial chemoembolization combined with Hippo/YAP inhibition significantly improve the survival of rats with transplanted hepatocellular carcinoma.
    Quan Y; Li Z; Zhu K; Liang J
    Lipids Health Dis; 2021 Jul; 20(1):74. PubMed ID: 34304741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of YAP/TAZ-TEAD activity induces cytotrophoblast differentiation into syncytiotrophoblast in human trophoblast.
    Mizutani T; Orisaka M; Miyazaki Y; Morichika R; Uesaka M; Miyamoto K; Yoshida Y
    Mol Hum Reprod; 2022 Sep; 28(10):. PubMed ID: 35993908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines".
    Sanna L; Piredda R; Marchesi I; Bordoni V; Forcales SV; Calvisi DF; Bagella L
    Chem Biol Interact; 2019 Oct; 312():108813. PubMed ID: 31494105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models.
    Barrette AM; Ronk H; Joshi T; Mussa Z; Mehrotra M; Bouras A; Nudelman G; Jesu Raj JG; Bozec D; Lam W; Houldsworth J; Yong R; Zaslavsky E; Hadjipanayis CG; Birtwistle MR; Tsankova NM
    Neuro Oncol; 2022 May; 24(5):694-707. PubMed ID: 34657158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
    Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
    Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present).
    Zagiel B; Melnyk P; Cotelle P
    Expert Opin Ther Pat; 2022 Aug; 32(8):899-912. PubMed ID: 35768160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 12. Verteporfin targeting YAP1/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells.
    Giraud J; Molina-Castro S; Seeneevassen L; Sifré E; Izotte J; Tiffon C; Staedel C; Boeuf H; Fernandez S; Barthelemy P; Megraud F; Lehours P; Dubus P; Varon C
    Int J Cancer; 2020 Apr; 146(8):2255-2267. PubMed ID: 31489619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yes-associated protein (YAP) and transcriptional coactivator with a PDZ-binding motif (TAZ): a nexus between hypoxia and cancer.
    Zhao C; Zeng C; Ye S; Dai X; He Q; Yang B; Zhu H
    Acta Pharm Sin B; 2020 Jun; 10(6):947-960. PubMed ID: 32642404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YAP/TAZ-TEAD is a novel transcriptional regulator of genes encoding steroidogenic enzymes in rat granulosa cells and KGN cells.
    Mizutani T; Orisaka M; Kawabe S; Morichika R; Uesaka M; Yoshida Y
    Mol Cell Endocrinol; 2023 Jan; 559():111808. PubMed ID: 36309205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vestigial-like family member 3 (VGLL3), a cofactor for TEAD transcription factors, promotes cancer cell proliferation by activating the Hippo pathway.
    Hori N; Okada K; Takakura Y; Takano H; Yamaguchi N; Yamaguchi N
    J Biol Chem; 2020 Jun; 295(26):8798-8807. PubMed ID: 32385107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Quinolinols as Activators of TEAD-Dependent Transcription.
    Pobbati AV; Mejuch T; Chakraborty S; Karatas H; Bharath SR; Guéret SM; Goy PA; Hahne G; Pahl A; Sievers S; Guccione E; Song H; Waldmann H; Hong W
    ACS Chem Biol; 2019 Dec; 14(12):2909-2921. PubMed ID: 31742995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging roles for the YAP/TAZ transcriptional regulators in brain tumour pathology and targeting options.
    Strepkos D; Markouli M; Papavassiliou KA; Papavassiliou AG; Piperi C
    Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12762. PubMed ID: 34409639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises.
    Ortega Á; Vera I; Diaz MP; Navarro C; Rojas M; Torres W; Parra H; Salazar J; De Sanctis JB; Bermúdez V
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapagliflozin delays renal fibrosis in diabetic kidney disease by inhibiting YAP/TAZ activation.
    Feng L; Chen Y; Li N; Yang X; Zhou L; Li H; Wang T; Xie M; Liu H
    Life Sci; 2023 Jun; 322():121671. PubMed ID: 37023953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the YAP-TEAD interaction interface for therapeutic intervention in glioblastoma.
    Saunders JT; Holmes B; Benavides-Serrato A; Kumar S; Nishimura RN; Gera J
    J Neurooncol; 2021 Apr; 152(2):217-231. PubMed ID: 33511508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.